Abstract
BackgroundThe current study investigated the motor and the non-motor outcomes of Nordic Walking (NW) in Parkinson's disease (PD) using a systematic review of studies with any design. MethodsThe search of PubMed, PsycInfo, Medline and SCOPUS until November 2018 identified k = 13 relevant studies: five randomised controlled-trials (RCTs) and eight observational studies. Study designs, intervention, patient and outcome details were coded. Study quality was assessed with the Physiotherapy Evidence Database scale. ResultsAll studies reported either benefits or no effects of NW in 318 patients at the early stages of PD with low to moderate severity. NW was well accepted and relatively safe. Symptom severity, walking speed and gait pattern consistently improved after 4 – 24 weeks of NW relative to baseline or any control condition during the ON-phases of pharmacotherapy. The NW benefits were less consistent during the OFF-phases and at the follow-up in the absence of regular training. ConclusionsNW may contribute to the maintenance of the overall mobility in addition to pharmacotherapy. Since the quality of studies was poor to moderate, future single-blind RCTs should investigate the clinical relevance of the NW outcomes and the training parameters necessary to optimise the benefits of NW in PD.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
